Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in …
…, GV Yamshchikov, S Hickman, S Schech, JN Hutter… - The Lancet, 2023 - thelancet.com
Background WHO has identified Marburg virus as an emerging virus requiring urgent vaccine
research and development, particularly due to its recent emergence in Ghana. We report …
research and development, particularly due to its recent emergence in Ghana. We report …
Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in …
…, NK Copeland, TA Crowell, JN Hutter… - The Lancet Infectious …, 2023 - thelancet.com
Background Zika virus infection is a threat to at-risk populations, causing major birth defects
and serious neurological complications. Development of a safe and efficacious Zika virus …
and serious neurological complications. Development of a safe and efficacious Zika virus …
A three-antigen Plasmodium falciparum DNA prime—Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled …
…, S Inoue, R Velasco, E Bergmann-Leitner, J Hutter… - PLoS …, 2021 - journals.plos.org
Background A DNA-prime/human adenovirus serotype 5 (HuAd5) boost vaccine encoding
Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP) and Pf apical membrane …
Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP) and Pf apical membrane …
First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly …
JN Hutter, PM Robben, C Lee, M Hamer, JE Moon… - Vaccine, 2022 - Elsevier
The global burden of malaria remains substantial. Circumsporozoite protein (CSP) has
been demonstrated to be an effective target antigen, however, improvements that offer more …
been demonstrated to be an effective target antigen, however, improvements that offer more …
Systematic review of Marburg virus vaccine nonhuman primate studies and human clinical trials
N Dulin, A Spanier, K Merino, JN Hutter, PE Waterman… - Vaccine, 2021 - Elsevier
Background Recent deadly outbreaks of Marburg virus underscore the need for an effective
vaccine. A summary of the latest research is needed for this WHO priority pathogen. This …
vaccine. A summary of the latest research is needed for this WHO priority pathogen. This …
Serological profiles of pan-coronavirus-specific responses in COVID-19 patients using a multiplexed electro-chemiluminescence-based testing platform
S Chaudhury, J Hutter, JS Bolton, S Hakre, E Mose… - PLoS …, 2021 - journals.plos.org
Serological assessment of SARS-CoV-2 specific responses are an essential tool for determining
the prevalence of past SARS-CoV-2 infections in the population especially when testing …
the prevalence of past SARS-CoV-2 infections in the population especially when testing …
[HTML][HTML] The CINAMR (Clinical Information Network-Antimicrobial Resistance) Project: A pilot microbial surveillance using hospitals linked to regional laboratories in …
…, B Mvera, R Musyimi, R Onsare, J Hutter… - Wellcome Open …, 2022 - ncbi.nlm.nih.gov
Background: Antimicrobial resistance (AMR) is a global threat and is thought to be acute in
low-and middle-income country (LMIC) settings, including in Kenya, but there is limited …
low-and middle-income country (LMIC) settings, including in Kenya, but there is limited …
Human papillomavirus infection
JN Hutter, CF Decker - Disease-a-Month, 2016 - Elsevier
Human papillomavirus (HPV) is a DNA virus that causes a variety of conditions including
common warts, condyloma acuminata (anogenital warts), and multiple malignancies involving …
common warts, condyloma acuminata (anogenital warts), and multiple malignancies involving …
Guidelines for the prevention of travel-associated illness in older adults
TK Lee, JN Hutter, J Masel, C Joya… - Tropical Diseases, Travel …, 2017 - Springer
International travel to the developing world is becoming more common in elderly patients (defined
here as individuals greater than 65 years old). When providing pre-travel counseling, …
here as individuals greater than 65 years old). When providing pre-travel counseling, …
SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1 …
BLO Shepherd, PT Scott, JN Hutter, C Lee… - The Lancet …, 2024 - thelancet.com
Background A self-assembling SARS-CoV-2 WA-1 recombinant spike ferritin nanoparticle (SpFN)
vaccine co-formulated with Army Liposomal Formulation (ALFQ) adjuvant containing …
vaccine co-formulated with Army Liposomal Formulation (ALFQ) adjuvant containing …
